Projects

This project assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials. By giving scientists access to the whole extent of our state-of-the-art facilities, cutting-edge services, advanced equipment and expertise, in an integrated way and with a common goal, we will accelerate the generation of new knowledge and intervention tools to enhance Europe’s capacity for controlling (re)emerging and epidemic infectious diseases.

Further information: https://isidore-project.eu/

Revolutionizing the drug repurposing landscape in Europe by developing a comprehensive, accessible and standardized platform that provides the expertise, tools and resources needed at all stages of the repurposing journey. Our recent contribution to this project includes the evaluation of the publicly available patent database, SureChEMBL, to chemically annotate existing drugs in terms of their similarity and clinical success from a drug repurposing perspective.

Further information: https://remedi4all.org/

Targeted degradation as a new mode of drug action): The ProxiDETECT sub-project aims to develop a versatile assay, screening and molecular profiling platform for the identification and characterisation of prodrug molecules, with a particular focus on molecular glues for the treatment of neurological diseases. It will extend the PROXIDRUGS toolbox to include a degradation-focused compound library, signal-on screening assays, novel reporter molecules and a platform for mechanistic studies in a disease-relevant cellular context.

Further information: https://www.proxidrugs.de/

Funded through the EU Horizon Europe programme, canSERV provides cutting edge, interdisciplinary and customised oncology services. It offers a comprehensive portfolio of oncology-related research services available to all scientists in EU member countries, associated countries and beyond. The ITMP is offering experimental services related to high-content image-based profiling of compounds and high-throughput microscopy services and generation and validation of in-vitro disease models and training services for cancer drug discovery – from target identification to drug approval and exploring high throughput biochemical and cellular assays in cancer drug discovery. These services are currently being adopted by partners at the University of Veterinary Medicine Vienna (Austria) and University of Florence (Italy), in particular assay development and screening of focussed compound libraries. It is anticiapted that the output will include understanding of disease biology and novel anti-cancer compounds.

Further information: https://www.canserv.eu/

To ensure that EU-OPENSCREEN continues to offer a comprehensive suite of relevant services and support a growing user community to conduct forefront research, IMPULSE will develop, validate and integrate new services in AI/ML, new chemical modalities, and innovative disease-relevant cell models combined with CRISPR-Cas9/RNAi-based genetic screening. The project will work towards the implementation of common operational and data standards to increase data reproducibility and FAIRness. Bespoke outreach and training activities will raise awareness among key user groups of its new services and advance operational excellence and reproducibility in pre-clinical drug discovery.

Further information: https://www.eu-openscreen.eu/impulse-overview.html